Full-Time

Medical Channel Excellence Lead

Updated on 9/16/2026

Deadline 9/21/26
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$274k - $456.6k/yr

+ 30% bonus target + Share-based long-term incentive program

No H1B Sponsorship

Cambridge, MA, USA + 3 more

More locations: Collegeville, PA, USA | Groton, CT, USA | New York, NY, USA

Remote

Relocation assistance may be available based on business needs or eligibility.

Bachelor's, Master's, PharmD, PhD, MD

Category
Biology & Biotech
Required Skills
Data Analysis

Get referred to Pfizer

See people who can refer or advise you

Requirements
  • A bachelor's degree with 15 or more years of experience in the pharmaceutical, biotechnology, healthcare, or related industries, including significant Medical Affairs leadership experience; a master's degree with 13 or more years; a PharmD or PhD with 10 or more years; or an MD with 9 or more years.
  • An advanced degree, preferably a scientific or healthcare-related degree such as an MD, PharmD, PhD, or equivalent.
  • Demonstrated success leading multifunctional teams, capability leaders, and complex strategic portfolios.
  • Experience in one or more of the following areas: digital medical engagement, omnichannel strategy, Medical Digital Health, strategic partnerships, channel standards, governance, or healthcare innovation.
  • Proven ability to set direction, make investment and resource decisions, and ensure execution through leaders in a matrixed organization.
  • Experience operating in a highly regulated environment and partnering effectively with Legal, Compliance, Governance, Digital, and other relevant functions.
  • A strong record of influencing senior stakeholders and leading organizational change.
  • Strategic leadership, organizational design, talent development, and succession planning.
  • Deep understanding of Medical Affairs, scientific engagement, and healthcare professional needs.
  • Knowledge of digital engagement, customer experience, data-informed channel strategy, Medical Digital Health, and emerging technologies, including artificial intelligence.
  • Ability to establish governance, standards, performance frameworks, and scalable operating models.
  • Strong business and financial acumen, judgment, executive communication, and external relationship management.
  • Commitment to quality, integrity, compliance, inclusion, accountability, and continuous improvement.
  • Authorization to be employed in the United States by any employer.
  • Permanent work authorization in the United States.
Responsibilities
  • Establish the vision, strategy, priorities, and operating model for Medical Channel Excellence in alignment with Medical Affairs objectives.
  • Lead the organization across the four Medical Channel Excellence capability areas and ensure each capability has clear objectives, decision rights, resources, and measures of success.
  • Translate Medical Affairs needs into portfolio priorities and provide direction to capability leaders responsible for developing and executing plans.
  • Build a high-performing leadership team by coaching, developing, and empowering leaders to make decisions and deliver through their teams.
  • Set expectations for accountability, collaboration, quality, inclusion, innovation, and continuous improvement across Medical Channel Excellence.
  • Guide workforce, succession, investment, and resource allocation decisions to sustain critical capabilities and deliver priority outcomes.
  • Represent Medical Channel Excellence in Medical Affairs leadership and planning forums and serve as a strategic advisor on digital scientific engagement and innovation.
  • Set the long-term vision and strategic roadmap for Medical Affairs digital engagement and channel capabilities.
  • Ensure the capability leadership team develops data-informed, customer-centered channel strategies aligned with Medical Affairs priorities and healthcare professional needs.
  • Guide priorities for owned and third-party medical channels, integrated engagement approaches, personalization, and emerging models of scientific exchange.
  • Sponsor capability development and innovation that improve the relevance, reach, integration, and measurable impact of medical scientific engagement.
  • Ensure appropriate performance frameworks are established to assess channel effectiveness, inform investment decisions, and drive continuous optimization.
  • Remove organizational barriers and enable collaboration among category and regional medical teams, Medical Content, Digital, Analytics, and other partner functions.
  • Define the strategic role and ambition of Medical Digital Health within Medical Affairs.
  • Set portfolio priorities and provide oversight for the evaluation, piloting, scaling, and lifecycle management of Medical Digital Health solutions led by the capability team.
  • Ensure Medical Digital Health priorities address defined Medical Affairs needs and support healthcare professional engagement, patient care, clinical decision-making, or healthcare delivery.
  • Guide investment choices related to emerging healthcare technologies, artificial intelligence, digital interventions, point-of-care capabilities, and other innovative approaches.
  • Ensure the Medical Digital Health team applies appropriate evidence, measurement, governance, quality, and compliance considerations to its portfolio.
  • Advise Medical Affairs leaders on the evolving Medical Digital Health landscape and implications for strategy, capability development, and future opportunities.
  • Establish the strategic partnership agenda for Medical Channel Excellence based on Medical Affairs priorities and capability needs.
  • Guide the partnership team in identifying, evaluating, structuring, and managing external collaborations with healthcare technology companies, digital platforms, healthcare organizations, professional networks, and other innovators.
  • Set expectations for partnership governance, strategic fit, performance, value realization, risk management, and lifecycle decisions.
  • Ensure the partnership portfolio complements internal capabilities and expands the reach, quality, or impact of Medical Affairs scientific engagement.
  • Serve as a senior Medical Affairs representative in selected external relationships and strategic collaborations.
  • Enable cross-functional alignment so partnership teams can execute efficiently and within appropriate legal, compliance, privacy, and governance requirements.
  • Set the vision and strategic framework for Medical Affairs channel standards, governance, and digital excellence.
  • Ensure the capability team develops, maintains, and operationalizes standards, requirements, playbooks, training, and governance processes for medical digital engagement.
  • Provide executive sponsorship for governance mechanisms that enable timely decisions, issue resolution, compliant innovation, and consistent application of standards.
  • Guide collaboration with Legal, Compliance, Governance, Medical Review, Digital, and relevant medical teams to align standards with changing regulations, policies, technologies, and channel requirements.
  • Ensure appropriate monitoring and performance measures are in place to assess adoption, quality, compliance, efficiency, and opportunities for improvement.
  • Champion scalable ways of working that reduce unnecessary complexity while maintaining appropriate quality and risk controls.
Desired Qualifications
  • An advanced degree, preferably a scientific or healthcare-related degree such as an MD, PharmD, PhD, or equivalent.

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose to $15 billion, and non-COVID products grew 5% operationally.
  • Pfizer raised 2026 guidance to $60.5 billion-$62.5 billion after Eliquis, Padcev, Vyndaqel strength.
  • Berobenatide entered Phase 3 planning, giving Pfizer a credible obesity franchise before 2028.

What critics are saying

  • Depo-Provera MDL exceeded 5,800 cases by July 2026, with late-2026 bellwethers looming.
  • Vyndamax still faces Apotex litigation in Delaware, preserving generic-entry uncertainty beyond 2031.
  • Ringaskiddy and Catania cuts show manufacturing contraction, signaling more restructuring through 2029.

What makes Pfizer unique

  • Seagen gives Pfizer leading ADCs: Padcev, Tivdak, Adcetris, Tucysa across oncology.
  • Pfizer still owns COMIRNATY distribution scale, with XFG vaccine approved August 27, 2026.
  • Vyndamax settlement extends U.S. exclusivity to June 1, 2031, stabilizing cardiomyopathy cash flows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-5%

1 year growth

-5%

2 year growth

-5%
Yahoo Finance
Sep 10th, 2026
Medicus Pharma secures Pfizer ADC deal with $2M funding, advances SkinJect for rare cancer treatment

Medicus Pharma has secured a development and licensing agreement with Pfizer for a CD228-targeted antibody-drug conjugate programme focused on solid tumours, including refractory melanoma. Pfizer is providing approximately $2 million in development funding, plus inventory and infrastructure support. CEO Dr Raza Bokhari said the deal allows Medicus to continue from where Pfizer concluded its Phase 1 dose-escalation work, strengthening the company's position in precision oncology. Medicus is also advancing its SkinJect programme for basal cell carcinoma. Final clinical trial results identified the 200-microgram patch as the optimal dose for future studies. The company is preparing for the FDA-approved pivotal SkinJect 005 study whilst recruiting patients. An independent reimbursement analysis suggests SkinJect could achieve reimbursement levels of $25,000 or more per patient.

Yahoo Finance
Sep 8th, 2026
AbbVie beats Pfizer as top dividend stock with 53-year payout streak and 203% growth

AbbVie offers a smarter long-term dividend investment than Pfizer, despite Pfizer's higher 6.1% yield. AbbVie holds Dividend King status with 53 consecutive years of dividend increases and raised its payout by 5.5% this year to $1.73 per share. Over the past decade, AbbVie increased its dividend by more than 203% compared to Pfizer's 51%. AbbVie's revenue grew 138% during this period, whilst Pfizer's rose just 18%. AbbVie successfully navigated Humira's patent cliff through home-grown immunology drugs Skyrizi and Rinvoq. By 2025, these two drugs generated combined annual sales exceeding $25 billion, replacing Humira's peak revenue and pushing total company revenue to record highs. AbbVie's free-cash-flow dividend payout ratio stands at 65%, lower than Pfizer's 89%.

Yahoo Finance
Aug 28th, 2026
Pfizer's updated COVID vaccine ships as FDA approves narrower rollout for over-65s and high-risk groups

Pfizer received FDA approval for its updated Comirnaty COVID-19 vaccine on Thursday, with deliveries to pharmacies and clinics beginning immediately. The company's shares were trading at $27.9079 on 28 August. However, the market opportunity has significantly narrowed from pandemic levels. Eligibility is now limited to adults aged 65 and older, plus higher-risk patients aged 5 through 64. Despite Comirnaty having distributed over five billion doses worldwide historically, today's revenue potential is considerably more constrained. Pfizer faces competition from Moderna and the Novavax-Sanofi protein vaccine for this smaller patient pool. The company's current share price sits 5.27% above its estimated value of $26.51, suggesting investors are paying a premium before actual uptake and commercial results become clear.

Associated Press
Aug 27th, 2026
FDA approves Pfizer-BioNTech XFG-adapted COVID-19 vaccine for high-risk groups

Pfizer and BioNTech have received US Food and Drug Administration (FDA) approval for their 2026-2027 COVID-19 vaccine targeting the XFG variant. The vaccine is approved for adults aged 65 and older, and individuals aged 5 to 64 with underlying conditions that increase risk of severe COVID-19 outcomes. The FDA approval is based on clinical, non-clinical and real-world data demonstrating the vaccine generates strong immune responses against currently circulating SARS-CoV-2 variants, including XFG and other contemporary lineages. The XFG variant was selected following FDA guidance for fall 2026 vaccine composition. The vaccine will begin shipping immediately and will be available in US pharmacies, hospitals and clinics within days. To date, more than five billion doses of COMIRNATY have been distributed globally.

Yahoo Finance
Aug 24th, 2026
Pfizer and J&J navigate patent cliffs with newer drugs offsetting blockbuster losses

Pfizer and Johnson & Johnson are navigating patent cliffs as key drugs lose exclusivity, with their latest results showing differing stages of transition. Pfizer's revenue excluding COVID products grew 5% operationally in Q2 2026, with newer medicines like Padcev and Vyndaqel contributing. The company expects $9.7 billion in cost savings through 2029 to support margins during the transition. Johnson & Johnson's Innovative Medicine sales rose 7.8%, despite Stelara revenue declining 55%. Tremfya sales surged 72.5% to $2 billion, helping offset losses alongside growth from oncology and neuroscience products. Johnson & Johnson raised 2026 guidance, with reported sales expected to reach $101.1 billion and adjusted EPS of $11.68. Its MedTech division provides additional diversification that pure pharmaceutical company Pfizer lacks, suggesting Johnson & Johnson's transition is more advanced.